Local 12: UC researchers study how to personalize COVID-19 treatments
The University of Cincinnati's Bingfang Yan, PhD, DVM, has received a $2.5 million National Institutes of Health grant to study how currently approved COVID-19 therapeutics can work together to create more effective and safe treatments for patients.
“The question we are asking is, can we combine two of those, or even three of those, that can produce better favor or more effective treatment?" Yan, professor and associate dean for research and innovation at UC's James L. Winkle College of Pharmacy, told Local 12 News.
Yan said finding out more about how these drugs can be given in combination will not only help treat COVID, but may be useful in treating other viruses like influenza.
Yan also spoke about the research on 55KRC's Simply Medicine radio show and podcast. Listen to the Simply Medicine interview. (Note: Segment begins around 17:55 mark of episode.)
Featured photo at top of remdesivir in an IV bag. Photo/Dimitri Karastelev/Unsplash.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.